Use of allopurinol for the treatment of hand foot skin reaction

• US 8,623,878 B2
• Filed: 04/29/2010
• Issued: 01/07/2014
• Est. Priority Date: 04/29/2009
• Status: Expired due to Fees

• Current Assignee: Advanced In Vitro Cell Technologies S.A., Nobera Pharma, S.L.
• Original Assignee: Advanced In Vitro Cell Technologies S.A., Nobera Pharma, S.L.
• Inventors: Rodemer, Yolanda
• Primary Examiner(s): Gembeh, Shirley V
• Application Number:
  US12/770,179
• Publication Number:
  US 20100280051A1
• Time in Patent Office: 1,349 Days
• Field of Search: 514/262.1
• US Class Current: 514/262.1
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/12 Keratolytics, e.g. wart or anti-corn preparations
• CPC Class Codes: A61P 17/16 Emollients or protectives, e.g. against radiation
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Use of allopurinol or a pharmaceutically acceptable salt thereof for the treatment or prevention of Hand Foot Skin Reaction (HFSR) induced by Multitargeted Kinase Inhibitor (MKI) therapy. The allopurinol or its salt is administered topically to the affected areas, palms and soles, preferably in the form of a cream.

Claims

1. A method for treating Hand Foot Skin Reaction (HFSR) induced by Multitargeted Kinase (MKI) therapy in a patient in need thereof, comprising administering to the patient a medicament having an amount of allopurinol or a pharmaceutically acceptable salt thereof which is therapeutically effective to treat Hand Foot Skin Reaction.

2. The method according to claim 1, wherein the HFSR is induced by sorafenib.

3. The method according to claim 2, wherein the medicament is administered topically to the skin of the hands or feet.

4. The method according to claim 2, wherein the medicament comprises about 1% to about 10% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

5. The method according to claim 4, wherein the medicament comprises about 1% to about 10% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

6. The method according to claim 1, wherein the HFSR is induced by sunitinib.

7. The method according to claim 6, wherein the medicament is administered topically to the skin of the hands or feet.

8. The method according to claim 6, wherein the medicament comprises about 1% to about 5% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

9. The method according to claim 8, wherein the medicament comprises about 1% to about 5% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

10. The method according to claim 1, wherein the medicament is administered topically to the skin.

11. The method according to claim 10, wherein the medicament is administered topically to the skin of the hands or feet.

12. The method according to claim 11, wherein the medicament comprises about 1% to about 10% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

13. The method according to claim 12, wherein the medicament comprises about 1% to about 5% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

14. The method according to claim 13, wherein the medicament comprises about 3% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

15. The method according to claim 1, wherein the medicament is a cream.

16. The method according to claim 15, wherein the medicament is a hydrophilic cream.

17. The method according to claim 1, wherein the medicament comprises about 1% to about 10% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

18. The method according to claim 17, wherein the medicament comprises about 1% to about 5% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

19. The method according to claim 18, wherein the medicament comprises about 3% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.